glp 1 compound tirzepatide FDA Ends Compounded GLP-1s: What

aRWD: real-world data from cohort or registry studies (electronic health records, insurance-claims databases), bSRS: adverse drug reaction evidence from case reports and spontaneous-reporting systems, such as the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization (WHO) VigiBase

If patches do eventually receive FDA approval, they could offer another convenient option, especially for patients who have difficulty with both injections and daily oral medications

However, GIPR agonism can potentially decrease the nauseous effects of GLP1 agonism by inhibiting area postrema inhibitory neurons

doi: 10.1038/5070 43 Medina-FrancoJLGiulianottiMAWelmakerGSHoughtenRA